Reed Jobs Lost His Father Steve To Cancer. Now His Cancer-Focused VC Firm Has Raised $200 Million.
Reed Jobs, the son of Apple founder Steve Jobs, has turned his personal tragedy into a mission to prevent others from suffering the same fate. At the age of 12, Reed’s world was shattered when his father was diagnosed with pancreatic cancer. Eight years later, Steve Jobs passed away at the age of 56, leaving a lasting impact on his son.
Determined to make a difference in the fight against cancer, Reed Jobs has become a prominent investor funding companies focused on innovative solutions to combat this deadly disease. With more than 600,000 people dying of cancer each year in the United States alone, Reed Jobs believes that significant progress can be made in turning cancer from a death sentence into a chronic, lifelong disease within his lifetime.
In 2023, Reed Jobs founded his own firm, Yosemite, named after the national park where his parents got married. With an initial fund of $263 million, Yosemite has since invested in approximately 20 companies dedicated to cancer research and treatment. Some of the notable companies in Yosemite’s portfolio include gene therapy firm Tune Therapeutics and AI drug development startup Chai Discovery.
Yosemite recently announced the successful raise of over $200 million for its second fund, with a targeted size of $350 million. The firm has attracted high-profile investors such as biotech giant Amgen, Memorial Sloan Kettering, MIT, and venture capitalist John Doerr. Reed Jobs’s mother, Laurene Powell Jobs, has also invested in the fund through Emerson Collective.
Yosemite’s focus spans the spectrum of cancers, from more treatable forms like colon cancer to the challenging cases like pancreatic cancer. Reed Jobs believes that early detection, targeted therapies, and continuous monitoring will play a crucial role in reducing cancer mortality rates in the future.
Despite managing over $1 billion in assets, Yosemite remains a relatively small player in the venture capital landscape. However, Reed Jobs’s personal connection to cancer and his commitment to making a meaningful impact in the field have garnered respect and admiration from his peers.
Reed Jobs’s unconventional approach to investing includes providing grants to scientists without any strings attached, giving them the freedom to pursue their research without financial constraints. This strategy has proven beneficial when researchers are ready to commercialize their discoveries, as Yosemite is already familiar with their work and can provide additional funding.
One of Yosemite’s success stories is Azalea Therapeutics, a gene therapy company that emerged from Nobel Prize winner Jennifer Doudna’s lab at UC Berkeley. With a focus on in vivo gene therapy, Azalea has the potential to revolutionize treatment methods for various diseases, including cancer.
Another promising investment by Yosemite is Chai Discovery, a startup utilizing AI technology to design proteins for developing new drugs. With a recent funding round led by General Catalyst and a partnership with Eli Lilly, Chai Discovery is making significant strides in creating innovative medicines for challenging diseases.
Reed Jobs’s dedication to advancing cancer research and treatment is fueled by a personal drive to make a difference in the fight against this devastating disease. Through Yosemite, he is paving the way for groundbreaking advancements in oncology and bringing hope to millions of patients and their families worldwide. Chai Discovery is poised to become a prominent player in the healthcare industry in the coming years, according to Reed Jobs, a key figure in the company. Jobs believes that Chai Discovery, along with other innovative companies, will play a crucial role in advancing cancer treatment and scientific research in America.
The advancements in cancer treatment over the past decade have been remarkable, with drugs like Keytruda from Merck generating billions in annual sales. Additionally, therapies such as CAR-T cell therapy and gene therapy have revolutionized the way we approach cancer treatment. These breakthroughs have paved the way for a new wave of companies focused on cutting-edge scientific discoveries.
Yosemite, the parent company of Chai Discovery, has recently received investments from major players in the healthcare industry, such as Amgen. This partnership highlights a shared commitment to fighting cancer and supporting groundbreaking scientific research.
Jobs envisions the new fund associated with Chai Discovery investing in around 25 companies, with a focus on areas like radiopharmaceuticals and AI-driven healthcare solutions. Gene therapy is a key area of interest for the company, as it represents a new frontier in cancer treatment. Additionally, cancer vaccines hold immense potential in both preventing and treating cancer, and Jobs is optimistic about their future impact.
As we enter a new era of scientific discovery and innovation, companies like Chai Discovery are at the forefront of driving progress in the fight against cancer. With a focus on groundbreaking research and cutting-edge technologies, these companies are shaping the future of healthcare and bringing hope to patients worldwide.
